Seroatlas · Human Serome Atlas

DYNLRB2

Dynein light chain roadblock-type 2

Also known as: DLRB2_HUMAN, DNCL2B, DNLC2B, ROBLD2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8TF09
Gene: DYNLRB2
Ensembl: ENSG00000168589
Chromosome: 16
Canonical length: 96 aa
Protein class: Predicted intracellular proteins
Quaternary structure: Homodimer

OverviewNCBI Gene

Predicted to enable dynein intermediate chain binding activity. Predicted to be involved in microtubule-based movement. Predicted to be located in ciliary tip. Predicted to be part of cytoplasmic dynein complex. Predicted to be active in centrosome and cytoplasm. Biomarker of hepatocellular carcinoma. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

96 residues, UniProt reviewed canonical sequence.

>Q8TF09|DYNLRB2
     1  MAEVEETLKR IQSHKGVIGT MVVNAEGIPI RTTLDNSTTV QYAGLLHHLT MKAKSTVRDI
    61  DPQNDLTFLR IRSKKHEIMV APDKEYLLIV IQNPCE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DYNLRB2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 158 nTPM

Expression across tissuesHPA

Tissue

testis: 158 nTPM
fallopian tube: 57 nTPM
choroid plexus: 55 nTPM
epididymis: 17 nTPM
hippocampal formation: 9.1 nTPM
hypothalamus: 8.8 nTPM

Single-cell type

late primary spermatocytes: 2,421 nCPM
early spermatids: 2,371 nCPM
late spermatids: 1,174 nCPM
epididymal efferent duct ciliated cells: 769 nCPM
respiratory ciliated cells: 729 nCPM
fallopian tube ciliated cells: 638 nCPM

Immune cell

neutrophil: 1.8 nTPM
naive CD8 T-cell: 1.3 nTPM
plasmacytoid DC: 1.3 nTPM
T-reg: 1.3 nTPM
naive CD4 T-cell: 0.6 nTPM
gdT-cell: 0.5 nTPM

Brain region

medulla oblongata: 20 nTPM
choroid plexus: 19 nTPM
midbrain: 19 nTPM
spinal cord: 12 nTPM
white matter: 12 nTPM
pons: 7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.84
gnomAD pLI: 0
gnomAD missense Z: -0.92
DepMap mean gene effect: 0.16
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

microtubule-based movement

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of DYNLRB2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DYNLRB2 as an antibody target. Whether an autoantibody or antibody against DYNLRB2 could matter depends on whether native DYNLRB2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DYNLRB2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label DYNLRB2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...